BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 23530504)

  • 1. Network pharmacology strategies toward multi-target anticancer therapies: from computational models to experimental design principles.
    Tang J; Aittokallio T
    Curr Pharm Des; 2014; 20(1):23-36. PubMed ID: 23530504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Target inhibition networks: predicting selective combinations of druggable targets to block cancer survival pathways.
    Tang J; Karhinen L; Xu T; Szwajda A; Yadav B; Wennerberg K; Aittokallio T
    PLoS Comput Biol; 2013; 9(9):e1003226. PubMed ID: 24068907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving the efficacy-safety balance of polypharmacology in multi-target drug discovery.
    Ravikumar B; Aittokallio T
    Expert Opin Drug Discov; 2018 Feb; 13(2):179-192. PubMed ID: 29233023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative and Systems Pharmacology. 1. In Silico Prediction of Drug-Target Interactions of Natural Products Enables New Targeted Cancer Therapy.
    Fang J; Wu Z; Cai C; Wang Q; Tang Y; Cheng F
    J Chem Inf Model; 2017 Nov; 57(11):2657-2671. PubMed ID: 28956927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Silico Oncology Drug Repositioning and Polypharmacology.
    Cheng F
    Methods Mol Biol; 2019; 1878():243-261. PubMed ID: 30378081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products.
    Kibble M; Saarinen N; Tang J; Wennerberg K; Mäkelä S; Aittokallio T
    Nat Prod Rep; 2015 Aug; 32(8):1249-66. PubMed ID: 26030402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. INTEGRATING GENETIC AND STRUCTURAL DATA ON HUMAN PROTEIN KINOME IN NETWORK-BASED MODELING OF KINASE SENSITIVITIES AND RESISTANCE TO TARGETED AND PERSONALIZED ANTICANCER DRUGS.
    Verkhivker GM
    Pac Symp Biocomput; 2016; 21():45-56. PubMed ID: 26776172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative and systems pharmacology 2. In silico polypharmacology of G protein-coupled receptor ligands via network-based approaches.
    Wu Z; Lu W; Yu W; Wang T; Li W; Liu G; Zhang H; Pang X; Huang J; Liu M; Cheng F; Tang Y
    Pharmacol Res; 2018 Mar; 129():400-413. PubMed ID: 29133212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico polypharmacology of natural products.
    Fang J; Liu C; Wang Q; Lin P; Cheng F
    Brief Bioinform; 2018 Nov; 19(6):1153-1171. PubMed ID: 28460068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using quantitative systems pharmacology for novel drug discovery.
    Pérez-Nueno VI
    Expert Opin Drug Discov; 2015 Dec; 10(12):1315-31. PubMed ID: 26328768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel computational approaches to polypharmacology as a means to define responses to individual drugs.
    Xie L; Xie L; Kinnings SL; Bourne PE
    Annu Rev Pharmacol Toxicol; 2012; 52():361-79. PubMed ID: 22017683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational Approaches Towards Kinases as Attractive Targets for Anticancer Drug Discovery and Development.
    Hameed R; Khan A; Khan S; Perveen S
    Anticancer Agents Med Chem; 2019; 19(5):592-598. PubMed ID: 30306880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Turning liabilities into opportunities: Off-target based drug repurposing in cancer.
    Palve V; Liao Y; Remsing Rix LL; Rix U
    Semin Cancer Biol; 2021 Jan; 68():209-229. PubMed ID: 32044472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational discovery of dual-indication multi-target PDE/Kinase inhibitor for precision anti-cancer therapy using structural systems pharmacology.
    Lim H; He D; Qiu Y; Krawczuk P; Sun X; Xie L
    PLoS Comput Biol; 2019 Jun; 15(6):e1006619. PubMed ID: 31206508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Network pharmacology: the next paradigm in drug discovery.
    Hopkins AL
    Nat Chem Biol; 2008 Nov; 4(11):682-90. PubMed ID: 18936753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated Analysis of Drug Sensitivity and Selectivity to Predict Synergistic Drug Combinations and Target Coaddictions in Cancer.
    Jaiswal A; Yadav B; Wennerberg K; Aittokallio T
    Methods Mol Biol; 2019; 1888():205-217. PubMed ID: 30519949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview on the current status of virtual high-throughput screening and combinatorial chemistry approaches in multi-target anticancer drug discovery; Part I.
    Geromichalos GD; Alifieris CE; Geromichalou EG; Trafalis DT
    J BUON; 2016; 21(4):764-779. PubMed ID: 27685895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective.
    Zhang W; Bai Y; Wang Y; Xiao W
    Curr Pharm Des; 2016; 22(21):3171-81. PubMed ID: 26907941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of drug candidates and repurposing opportunities through compound-target interaction networks.
    Cichonska A; Rousu J; Aittokallio T
    Expert Opin Drug Discov; 2015 Dec; 10(12):1333-45. PubMed ID: 26429153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.